Literature DB >> 10718025

Are pharmaceuticals cost-effective? A review of the evidence.

P J Neumann, E A Sandberg, C M Bell, P W Stone, R H Chapman.   

Abstract

The argument that prescription drugs are cost-effective has been made both by the pharmaceutical industry to support rising drug prices and expenditures, and by advocates of expanded drug coverage for elderly and low-income persons. A new database of 228 published cost-utility analyses sheds light on the issue. According to published data, some drugs do save money or are cost-effective, but the issue depends critically on the context in which the drug is used and the intervention with which it is compared. Cost-utility analyses funded by the drug industry tend to report more favorable results than do those funded by nonindustry sources. Cost-effectiveness analysis can help policymakers to determine whether drugs and other interventions offer value for money.

Entities:  

Mesh:

Year:  2000        PMID: 10718025     DOI: 10.1377/hlthaff.19.2.92

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  46 in total

Review 1.  Pharmaceutical industry sponsorship and research outcome and quality: systematic review.

Authors:  Joel Lexchin; Lisa A Bero; Benjamin Djulbegovic; Otavio Clark
Journal:  BMJ       Date:  2003-05-31

Review 2.  Bias in published cost effectiveness studies: systematic review.

Authors:  Chaim M Bell; David R Urbach; Joel G Ray; Ahmed Bayoumi; Allison B Rosen; Dan Greenberg; Peter J Neumann
Journal:  BMJ       Date:  2006-02-22

3.  Is fidaxomicin worth the cost? An economic analysis.

Authors:  Sarah M Bartsch; Craig A Umscheid; Neil Fishman; Bruce Y Lee
Journal:  Clin Infect Dis       Date:  2013-05-23       Impact factor: 9.079

4.  Methodological reviews of economic evaluations in health care: what do they target?

Authors:  Maria-Florencia Hutter; Roberto Rodríguez-Ibeas; Fernando Antonanzas
Journal:  Eur J Health Econ       Date:  2013-08-24

Review 5.  Present challenges in cervical cancer prevention: Answers from cost-effectiveness analyses.

Authors:  Mireia Diaz; Silvia de Sanjosé; F Xavier Bosch; Laia Bruni
Journal:  Rep Pract Oncol Radiother       Date:  2018-04-26

6.  30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement.

Authors:  Peter J Neumann; Chi-Hui Fang; Joshua T Cohen
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

7.  The increasingly complex fourth hurdle for pharmaceuticals.

Authors:  Joshua Cohen; Elly Stolk; Maartje Niezen
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

Review 8.  Cost-effectiveness analysis and HIV screening: the emergency medicine perspective.

Authors:  Heather Hsu; Rochelle P Walensky
Journal:  Ann Emerg Med       Date:  2011-07       Impact factor: 5.721

9.  Clinical Benefits, Harms, and Cost-Effectiveness of Breast Cancer Screening for Survivors of Childhood Cancer Treated With Chest Radiation : A Comparative Modeling Study.

Authors:  Jennifer M Yeh; Kathryn P Lowry; Clyde B Schechter; Lisa R Diller; Oguzhan Alagoz; Gregory T Armstrong; John M Hampton; Wendy Leisenring; Qi Liu; Jeanne S Mandelblatt; Diana L Miglioretti; Chaya S Moskowitz; Kevin C Oeffinger; Amy Trentham-Dietz; Natasha K Stout
Journal:  Ann Intern Med       Date:  2020-07-07       Impact factor: 25.391

10.  Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes zoster.

Authors:  Tracy A Lieu; G Thomas Ray; Ismael R Ortega-Sanchez; Ken Kleinman; Donna Rusinak; Lisa A Prosser
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.